CY1121320T1 - Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων - Google Patents
Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιωνInfo
- Publication number
- CY1121320T1 CY1121320T1 CY20191100096T CY191100096T CY1121320T1 CY 1121320 T1 CY1121320 T1 CY 1121320T1 CY 20191100096 T CY20191100096 T CY 20191100096T CY 191100096 T CY191100096 T CY 191100096T CY 1121320 T1 CY1121320 T1 CY 1121320T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hydrogen
- aryl
- modifiing
- hormond
- kidney
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μια μέθοδο θεραπείας μιας ασθένειας ή διαταραχής που χαρακτηρίζεται από αυξημένα επίπεδα ορμονών του στρες και/ή μειωμένα επίπεδα ανδρογόνων ορμονών σε ένα υποκείμενο, που περιλαμβάνει τη χορήγηση στο υποκείμενο μιας θεραπευτικώς αποτελεσματικής ποσότητας μιας ένωσης που αντιπροσωπεύεται από τον τύπο (I): όπου το n είναι 1 ή 3· το R είναι υδρογόνο ή --C(O)N(Ra)(Rb) όπου το Ra και Rb είναι ανεξάρτητα --(C1-C4) αλκύλιο, ή --(C1-C4) αλκυλ-(C5-C7) αρύλιο, καθένα από τα Ra και Rb είναι προαιρετικά υποκατεστημένο από --(C1-C4) αλκόξυ· τα R1, R2 και R3, είναι ανεξάρτητα υδρογόνο, αλογόνο, κυανό ή --(C6-C10) αρύλιο, όπου το εν λόγω --(C6-C10) αρύλιο είναι προαιρετικά υποκατεστημένο από αλογόνο, με την προϋπόθεση ότι όχι περισσότερο από ένα από τα R1, R2 και R3 είναι υδρογόνο· και τα R4 και R5 είναι υδρογόνο· ή ένα φαρμακευτικώς αποδεκτό άλας αυτών.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29498010P | 2010-01-14 | 2010-01-14 | |
| PCT/US2011/021100 WO2011088188A1 (en) | 2010-01-14 | 2011-01-13 | Use of an adrenal hormone-modifying agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121320T1 true CY1121320T1 (el) | 2020-05-29 |
Family
ID=43735742
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100096T CY1121320T1 (el) | 2010-01-14 | 2019-01-24 | Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων |
| CY2020018C CY2020018I2 (el) | 2010-01-14 | 2020-07-08 | Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2020018C CY2020018I2 (el) | 2010-01-14 | 2020-07-08 | Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8609862B2 (el) |
| EP (2) | EP2523731B1 (el) |
| JP (4) | JP5602250B2 (el) |
| KR (1) | KR101412206B1 (el) |
| CN (2) | CN105440038A (el) |
| AU (1) | AU2011205290C1 (el) |
| BR (1) | BR112012017458B1 (el) |
| CA (1) | CA2786443C (el) |
| CL (1) | CL2012001961A1 (el) |
| CY (2) | CY1121320T1 (el) |
| DK (1) | DK2523731T3 (el) |
| ES (1) | ES2707596T3 (el) |
| HR (1) | HRP20190064T1 (el) |
| HU (2) | HUE041967T2 (el) |
| IL (1) | IL220804A0 (el) |
| LT (2) | LT2523731T (el) |
| LU (1) | LUC00159I2 (el) |
| MA (1) | MA33904B1 (el) |
| ME (1) | ME03371B (el) |
| MX (2) | MX354022B (el) |
| NL (1) | NL301043I2 (el) |
| NO (1) | NO2020012I1 (el) |
| NZ (1) | NZ601077A (el) |
| PL (1) | PL2523731T3 (el) |
| PT (1) | PT2523731T (el) |
| RS (1) | RS58234B1 (el) |
| RU (1) | RU2598708C2 (el) |
| SG (1) | SG182393A1 (el) |
| SI (1) | SI2523731T1 (el) |
| TN (1) | TN2012000352A1 (el) |
| TR (1) | TR201900515T4 (el) |
| WO (1) | WO2011088188A1 (el) |
| ZA (1) | ZA201205058B (el) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5602250B2 (ja) * | 2010-01-14 | 2014-10-08 | ノバルティス アーゲー | 副腎ホルモン修飾剤の使用 |
| CN103037864A (zh) | 2010-06-16 | 2013-04-10 | 安比拉神经疗法公司 | 用于治疗成瘾、精神障碍和神经变性疾病的组合物和方法 |
| AR086665A1 (es) | 2011-06-14 | 2014-01-15 | Lilly Co Eli | Inhibidor de aldosterona sintasa y composiciones farmaceuticas |
| EP2757883B1 (en) | 2011-09-22 | 2021-01-13 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| EP2757882B1 (en) | 2011-09-22 | 2020-11-04 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| US9351973B2 (en) | 2011-09-22 | 2016-05-31 | Merck Sharp & Dohme Corp. | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
| CA2863339C (en) * | 2012-01-17 | 2021-03-23 | Novartis Ag | Forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor |
| EP2836228B1 (en) * | 2012-04-12 | 2024-03-20 | Novartis AG | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
| WO2014055595A1 (en) | 2012-10-05 | 2014-04-10 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitiors related applications |
| JP2015093832A (ja) * | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
| MX2016017315A (es) * | 2014-07-07 | 2017-04-27 | Novartis Ag | Formas de dosificacion farmaceutica. |
| WO2016048984A1 (en) * | 2014-09-25 | 2016-03-31 | Cortendo Ab (Publ) | Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole |
| AU2016210899B2 (en) * | 2015-01-29 | 2019-03-07 | Recordati Ag | Process for the production of condensed imidazolo Derivatives |
| WO2016164476A2 (en) | 2015-04-06 | 2016-10-13 | Millendo Therapeutics, Inc. | Combination therapy for treating disorders associated with excess cortisol production |
| CA2990413A1 (en) * | 2015-06-22 | 2016-12-29 | Embera Neurotherapeutics, Inc. | Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders |
| CA3055940A1 (en) | 2017-03-10 | 2018-09-13 | Embera Neurotherapeutics, Inc. | Pharmaceutical compositions and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US4814333A (en) | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| US5503843A (en) * | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
| US5658881A (en) | 1994-10-14 | 1997-08-19 | Twk, Inc. | Method for topical inhibition of the metabolic activity of cytochrome P450 |
| DE19814087A1 (de) * | 1998-03-30 | 1999-10-14 | Lohmann Therapie Syst Lts | Feuchtigkeitsaktivierbares therapeutisches System |
| DK1121111T3 (da) | 1998-10-15 | 2010-05-31 | Imp Innovations Ltd | Forbindelser til behandling af vægttab |
| WO2002066468A2 (en) | 2001-02-16 | 2002-08-29 | Aventis Pharmaceuticals Inc. | Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands |
| TWI263640B (en) | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| JP5138875B2 (ja) | 2005-07-19 | 2013-02-06 | 株式会社デンソー | センサ装置 |
| GT200600381A (es) * | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| TW200804378A (en) | 2005-12-09 | 2008-01-16 | Speedel Experimenta Ag | Organic compounds |
| CA2645678A1 (en) | 2006-03-16 | 2007-09-20 | Yeda Research And Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| BRPI0712557A2 (pt) * | 2006-05-26 | 2013-07-02 | Novartis Ag | inibidores de aldosterona sintase e/ou 11 beta-hidrolase |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| CA2660701A1 (en) * | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| AU2007333902A1 (en) * | 2006-12-18 | 2008-06-26 | Novartis Ag | 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives and their use as aldosterone/11-beta-hydroxylase inhibitors |
| EP2095819A1 (en) * | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
| AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
| JP5602250B2 (ja) * | 2010-01-14 | 2014-10-08 | ノバルティス アーゲー | 副腎ホルモン修飾剤の使用 |
| CA2863339C (en) * | 2012-01-17 | 2021-03-23 | Novartis Ag | Forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor |
| EP2836228B1 (en) * | 2012-04-12 | 2024-03-20 | Novartis AG | Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors |
-
2011
- 2011-01-13 JP JP2012549066A patent/JP5602250B2/ja active Active
- 2011-01-13 TR TR2019/00515T patent/TR201900515T4/tr unknown
- 2011-01-13 LT LTEP11702096.6T patent/LT2523731T/lt unknown
- 2011-01-13 CN CN201510632085.XA patent/CN105440038A/zh active Pending
- 2011-01-13 SI SI201131654T patent/SI2523731T1/sl unknown
- 2011-01-13 MA MA35039A patent/MA33904B1/fr unknown
- 2011-01-13 RU RU2012134510/15A patent/RU2598708C2/ru active
- 2011-01-13 MX MX2014011700A patent/MX354022B/es unknown
- 2011-01-13 BR BR112012017458-4A patent/BR112012017458B1/pt active IP Right Grant
- 2011-01-13 PL PL11702096T patent/PL2523731T3/pl unknown
- 2011-01-13 HU HUE11702096A patent/HUE041967T2/hu unknown
- 2011-01-13 CA CA2786443A patent/CA2786443C/en active Active
- 2011-01-13 CN CN201180006082.5A patent/CN102711916B/zh active Active
- 2011-01-13 AU AU2011205290A patent/AU2011205290C1/en active Active
- 2011-01-13 EP EP11702096.6A patent/EP2523731B1/en active Active
- 2011-01-13 KR KR1020127021180A patent/KR101412206B1/ko active Application Filing
- 2011-01-13 RS RS20190043A patent/RS58234B1/sr unknown
- 2011-01-13 MX MX2012008212A patent/MX2012008212A/es active IP Right Grant
- 2011-01-13 ME MEP-2019-8A patent/ME03371B/me unknown
- 2011-01-13 PT PT11702096T patent/PT2523731T/pt unknown
- 2011-01-13 EP EP18201925.7A patent/EP3527208A1/en not_active Withdrawn
- 2011-01-13 WO PCT/US2011/021100 patent/WO2011088188A1/en active Application Filing
- 2011-01-13 DK DK11702096.6T patent/DK2523731T3/en active
- 2011-01-13 NZ NZ601077A patent/NZ601077A/en unknown
- 2011-01-13 US US13/521,548 patent/US8609862B2/en active Active
- 2011-01-13 ES ES11702096T patent/ES2707596T3/es active Active
- 2011-01-13 SG SG2012049995A patent/SG182393A1/en unknown
-
2012
- 2012-07-05 IL IL220804A patent/IL220804A0/en active IP Right Grant
- 2012-07-06 TN TNP2012000352A patent/TN2012000352A1/en unknown
- 2012-07-06 ZA ZA2012/05058A patent/ZA201205058B/en unknown
- 2012-07-13 CL CL2012001961A patent/CL2012001961A1/es unknown
-
2013
- 2013-11-13 US US14/079,018 patent/US9434754B2/en active Active
-
2014
- 2014-07-04 JP JP2014139066A patent/JP6181610B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139449A patent/JP6425688B2/ja active Active
-
2018
- 2018-05-01 JP JP2018087986A patent/JP2018150326A/ja active Pending
-
2019
- 2019-01-09 HR HRP20190064TT patent/HRP20190064T1/hr unknown
- 2019-01-24 CY CY20191100096T patent/CY1121320T1/el unknown
-
2020
- 2020-06-09 NO NO2020012C patent/NO2020012I1/no unknown
- 2020-06-10 NL NL301043C patent/NL301043I2/nl unknown
- 2020-06-16 LU LU00159C patent/LUC00159I2/fr unknown
- 2020-06-19 LT LTPA2020512C patent/LTC2523731I2/lt unknown
- 2020-06-23 HU HUS2000018C patent/HUS000508I2/hu unknown
- 2020-07-08 CY CY2020018C patent/CY2020018I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121320T1 (el) | Χρηση ενος παραγοντα τροποποιησης ορμονων των επινεφριδιων | |
| CY1119642T1 (el) | Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου | |
| CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
| CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
| CY1120104T1 (el) | Αναστολεις της syk | |
| CY1122498T1 (el) | Δευτεριωμενα παραγωγα ιβακαφτορης | |
| EA201291414A1 (ru) | Имидазопиридиновые производные, способ их получения и терапевтическое использование | |
| EA201291409A1 (ru) | Производные индолизина, способ их получения и их терапевтическое применение | |
| CY1121847T1 (el) | Παραγωγα 1-((3-((1-πιπεραζινυλο)καρβονυλο)φαινυλο)μεθυλο)-2,4(1η,3η)-κιναζολινοδιονης ως αναστολεις parp για τη θεραπεια του καρκινου | |
| CY1118464T1 (el) | Cetp αναστολεας τυπου συγχωνευμενης δικυκλικης οξαζολιδινονης | |
| EA201591457A8 (ru) | Терапевтические соединения | |
| EA201500300A1 (ru) | Способы применения с-мет-модуляторов | |
| EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
| EA201590693A1 (ru) | Ингибиторы gdf-8 | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| CY1118371T1 (el) | Αναστολεις του iap | |
| EA201270752A1 (ru) | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью | |
| CY1119425T1 (el) | Ενωσεις φαινοξυαιθυλο πιπεριδινης | |
| EA201171062A1 (ru) | Алкиламидные соединения и их применение | |
| EA200800294A1 (ru) | Способы нейропротекции | |
| EA201301301A1 (ru) | Производные тиазола | |
| EA201490846A1 (ru) | Новые производные арилхинолина | |
| EA201491820A1 (ru) | Новые тиенопиримидиновые производные, способы их получения и их терапевтические применения | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| EA201600241A1 (ru) | Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты |